Analysis on research status and hot spots of gabapentinoid drugs in the treatment of pain
- VernacularTitle:加巴喷丁类药物在疼痛治疗中的研究现状及热点分析
- Author:
Xiaojing LU
1
;
Xiangfen SHI
1
;
Fangying SI
1
;
Yuanxia ZHAO
1
;
Jinyuan XING
1
;
Xufeng ZHANG
1
;
Xiaoyu ZHAO
1
;
Shuzhang DU
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Zhengzhou University，Zhengzhou 450052，China
- Publication Type:Journal Article
- Keywords:
gabapentinoid drugs;
pain treatm ent;
bibliometrics;
visualization;
VOSviewer;
CiteSpace
- From:
China Pharmacy
2022;33(8):996-1002
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the si tuation and hot spots of gabapentinoid drugs in the treatment of pain. METHODS Related researches about gabapentinoid drugs in the treatment of pain were retrieved from Web of Science core collection database during Jan. 1st，2011-Dec. 31st，2020. VOSviewer 1.6.17，CiteSpace 5.8.R1 and Excel 2018 software were used to statistically analyze the key characteristics of relevant literature ，such as the annual publications ，countries/regions，institutions，authors， journals and research hot spots. RESULTS & CONCLUSIONS A total of 3 519 literatures were retrieved ，and the annual publication outputs showed an upward trend generally. Totally 86 countries/regions had conducted relevant studies ，of which the United States ranked first （up to 1 219），and had close cooperation with the United Kingdom ，Canada，China，Germany，Japan， etc；a total of 3 996 institutions had published relevant literatures ，and the Pfizer Inc. issued the most publications ；the most studies were devoted by Professor Parsons from the University of California San Diego ，and the highest co-citations author was Professor Gilron from the Queen ’s University. Among 1 185 journals，Pain ranked first not only in the high-productive journal ，but also in the co-cited journal. The main hot topics include abuse and misuse of gabapentinoid ，off-label use of gabapentinoid ，clinical application of gabapentinoid as a component of multimodal analgesia ，and the update of guidelines for pain based on systematic evaluation and meta-analysis.
